Background Mifepristone (MF) has been largely used in reproductive medicine due to its
capacity to modulate the progesterone receptor (PR). The study of MF has been expanded …

Background Recent clinical trials on ovarian cancer with mifepristone (MF) have failed,
despite in vitro findings on its strong progesterone (P4) antagonist function. Methods …

Purpose: These studies were designed to determine whether the synthetic steroid
mifepristone inhibits ovarian cancer growth in vitro and in vivo and the molecular …

Background The prototypical antiprogestin mifepristone exhibits potent growth inhibition
activity towards ovarian cancer cells in vitro and in vivo. The aim of this research was to …

Importance of the field: Mifepristone is a synthetic selective progesterone-receptor modulator
(SPRM) that is widely used around the globe in the field of reproductive medicine. At present …

Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …

Background Uveal melanoma (UM), the most prevalent intraocular tumor in adults, is a
highly metastatic and drug resistant lesion. Recent studies have demonstrated cytotoxic and …

Purpose To determine the growth inhibitory effects of mifepristone on endometrial cancer
cell growth and evaluate its effect on apoptosis using HEC-1-A and Ishikawa human …

The effects of antiprogestin mifepristone (MF) on the growth, progesterone receptor
expression and cell cycle kinetics of several human ovarian epithelial carcinoma (OEC) cell …

We have previously shown that the antiprogestin and antiglucocorticoid mifepristone inhibits
the growth of ovarian cancer cells. In this work, we hypothesized that cellular stress caused …